Heard On The Street: April 2011

Published on by on April 1, 2011

March saw a flurry of activity in the ETF industry, with two new issuers debuting and more than two dozen new products hitting the market. The month saw continued pressure on fees in the industry, with a new leader atop the “cheapest ETF” leaderboard and new options for commission-free trading on a major brokerage platform.

Major developments in the industry weren’t limited to new products; market leader iShares received SEC approval to launch active ETFs, a step that could accelerate the growth of a corner of the market that is believed to hold tremendous potential but so far has been slow to gain traction with investors. Both existing ETF issuers and potential players awaiting regulatory approval are no doubt watching carefully, and the coming months could have a major impact on the future of the active ETF industry.

Pro Membership Required to Continue Reading ETFdb Pro

To continue reading this article, you must be an ETFdb Pro member. Please login or begin your 14-day free trial to continue reading. There are several benefits to becoming an ETFdb Pro member today:
  • Register on ETFdbAccess to 50+ All-ETF model portfolios. Whether you're a long-term, buy-and-hold investor or a more active trader looking to establish a tactical position, our collection of ETFdb Portfolios has something for everyone.
  • ETFdb Realtime Ratings show you exactly where each fund stacks up next to the competition. Get objective, in-depth, custom research on every ETF.
  • Pro members have Unlimited Excel Download capabilities across the entire database; users can easily download more than 200 data filled paged and also export results to Microsoft Excel from every tool.
  • Get ETF Picks of the Month. For active investors seeking ETF investment ideas, our team analyzes technical and fundamental price drivers of more than 1,400 ETFs to identify both short and longer-term opportunities with a focus on absolute returns. Recommendations are actionable investment ideas that are poised for outperformance over the next week to 90 days.

Begin Your Free 14-Day Trial Now